Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?

키워드

참고문헌 (65)

1. Global Burden of Disease Liver Cancer Collaboration, "The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level : results from the Global Burden of Disease Study 2015", JAMA Oncol, 3, pp.1683~1691 (2017)
2. 김보현, "Epidemiology of liver cancer in South Korea", Clinical and Molecular Hepatology, 24(1), pp.1~9 (2018), 대한간학회
3. 이재승, "Conditional Survival Estimates Improve Over Time for Patients with Hepatocellular Carcinoma: An Analysis for Nationwide Korea Cancer Registry Database", Cancer Research and Treatment, 51(4), pp.1347~1356 (2019), 대한암학회
4. Thomas MB, "Hepatocellular carcinoma : consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting", J Clin Oncol, 28, pp.3994~4005 (2010)
5. European Association for the Study of the Liver, "Management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
6. Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
7. Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma : 2018 practice guidance by the American Association for the Study of Liver Diseases", Hepatology, 68, pp.723~750 (2018)
8. Bruix J, "Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet, 389, pp.56~66 (2017)
9. Abou-Alfa GK, "Cabozantinib in patients with advanced and progressing hepatocellular carcinoma", N Engl J Med, 379, pp.54~63 (2018)
10. Zhu AX, "Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations(REACH-2) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet Oncol, 20, pp.282~296 (2019)
11. Schreiber RD, "Cancer immunoediting : integrating immunity's roles in cancer suppression and promotion", Science, 331, pp.1565~1570 (2011)
12. Iñarrairaegui M, "Immunotherapy of hepatocellular carcinoma : facts and hopes", Clin Cancer Res, 24, pp.1518~1524 (2018)
13. Jenne CN, "Immune surveillance by the liver", Nat Immunol, 14, pp.996~1006 (2013)
14. Severi T, "Tumor initiation and progression in hepatocellular carcinoma : risk factors, classification, and therapeutic targets", Acta Pharmacol Sin, 31, pp.1409~1420 (2010)
15. Fu Y, "From bench to bed : the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma", J Exp Clin Cancer Res, 38, pp.396~ (2019)
16. Cariani E, "Immune landscape of hepatocellular carcinoma microenvironment : implications for prognosis and therapeutic applications", Liver Int, 39, pp.1608~1621 (2019)
17. Prieto J, "Immunological landscape and immunotherapy of hepatocellular carcinoma", Nat Rev Gastroenterol Hepatol, 12, pp.681~700 (2015)
18. Chon YE, "Development of a new nomogram including neutrophil-to-lymphocyte ratio to predict survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization", Cancers(Basel), 11, pp.E509~ (2019)
19. Kondo Y, "Significant roles of regulatory T cells and myeloid derived suppressor cells in hepatitis B virus persistent infection and hepatitis B virus-related HCCs", Int J Mol Sci, 16, pp.3307~3322 (2015)
20. Liu M, "Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma", Gut, 69, pp.365~379 (2020)
21. Dardalhon V, "Tim-3", galectin-9 pathway : regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells, 2010, pp.185, 1383~1392
22. Hoechst B, "Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor", Hepatology, 50, pp.799~807 (2009)
23. Yan W, "Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages", Gut, 64, pp.1593~1604 (2015)
24. Huang W, "Interleukin-8 induces expression of FOXC1 to promote transactivation of CXCR1 and CCL2 in hepatocellular carcinoma cell lines and formation of metastases in mice", Gastroenterology, 149, pp.1053~1067 (2015)
25. Cai H, "Colony-stimulating factor-1-induced AIF1 expression in tumor-associated macrophages enhances the progression of hepatocellular carcinoma", OncoImmunology, 6, pp.e1333213~ (2017)
26. Gabrilovich DI, "Coordinated regulation of myeloid cells by tumours", Nat Rev Immunol, 12, pp.253~268 (2012)
27. Hasmim M, "Critical role of tumor microenvironment in shaping NK cell functions : implication of hypoxic stress", Front Immunol, 6, pp.482~ (2015)
28. Yamamoto M, "α-Fetoprotein impairs activation of natural killer cells by inhibiting the function of dendritic cells", Clin Exp Immunol, 165, pp.211~219 (2011)
29. Li T, "Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO", Cancer Lett, 318, pp.154~161 (2012)
30. Muhanna N, "Amelioration of hepatic fibrosis by NK cell activation", Gut, 60, pp.90~98 (2011)
31. Zhou SL, "A positive feedback loop between cancer stem-like cells and tumor-associated neutrophils controls hepatocellular carcinoma progression", Hepatology, 70, pp.1214~1230 (2019)
32. Wan S, "Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells", Gastroenterology, 147, pp.1393~1404 (2014)
33. El-Khoueiry AB, "Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040) : an open-label, non-comparative, phase 1", 2 dose escalation and expansion trial, 2017, pp.389, 2492~2502
34. Yau T, "LBA38_PR-CheckMate 459 : A randomized, multi-center phase III study of nivolumab(NIVO)vs sorafenib(SOR)as first-line(1L)treatment in patients(pts)with advanced hepatocellular carcinoma(aHCC)", Ann Oncol, 30, pp.v874~ (2019)
35. Liu X, "Immune checkpoint inhibitors in hepatocellular carcinoma : opportunities and challenges", Oncologist, 24, pp.S3~ (2019)
36. Kudo M, "Pembrolizumab for the treatment of hepatocellular carcinoma", Liver Cancer, 8, pp.143~154 (2019)
37. Zhu AX, "Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224) : a non-randomised, open-label phase 2 trial", Lancet Oncol, 19, pp.940~952 (2018)
38. Finn RS, "Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240 : a randomized, double-blind, phase III trial", J Clin Oncol, 38, pp.193~202 (2020)
39. Okusaka T, "Immunotherapy for hepatocellular carcinoma : current status and future perspectives", ESMO Open, 3, pp.e000455~ (2018)
40. Qin S, "A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma", J Clin Oncol, 36, pp.TPS3110~ (2018)
41. Huang J, "Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors", J Clin Oncol, 35, pp.e15572~ (2017)
42. Qin SK, "LBA27-A randomized multicentered phase II study to evaluate SHR-1210(PD-1 antibody)in subjects with advanced hepatocellular carcinoma(HCC)who failed or intolerable to prior systemic treatment", Ann Oncol, 29, pp.mdy424~ (2018)
43. Wainberg ZA, "Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma(HCC)", J Clin Oncol, 35, pp.4071~ (2017)
44. Kelley RK, "Phase I", II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma(HCC) : phase I safety and efficacy analyses, 2017, pp.35, 4073~
45. Abou-Alfa GK, "A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study", J Clin Oncol, 36, pp.TPS4144~ (2018)
46. Pishvaian MJ, "LBA26-Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma(HCC)", Ann Oncol, 29, pp.mdy424028~ (2018)
47. Finn RS, "IMbrave150 : A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma", J Clin Oncol, 36, pp.TPS4141~ (2018)
48. Sangro B, "A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C", J Hepatol, 59, pp.81~88 (2013)
49. Duffy AG, "Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma", J Hepatol, 66, pp.545~551 (2017)
50. Monney L, "Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease", Nature, 415, pp.536~541 (2002)
51. Mohanty R, "CAR T cell therapy : a new era for cancer treatment(Review)", Oncol Rep, 42, pp.2183~2195 (2019)
52. Lee JH, "Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma", Gastroenterology, 148, pp.1383~1391 (2015)
53. Giannini EG, "Overview of immune checkpoint inhibitors therapy for hepatocellular carcinoma, and the ITA.LI", Cancers(Basel), 11, pp.E1689~ (2019)
54. Hanahan D, "Accessories to the crime : functions of cells recruited to the tumor microenvironment", Cancer Cell, 21, pp.309~322 (2012)
55. Ikeda M, "A phase 1b trial of lenvatinib(LEN)plus pembrolizumab(PEM)in patients(pts)with unresectable hepatocellular carcinoma(uHCC)", J Clin Oncol, 36, pp.4076~ (2018)
56. Kudo M, "First-line avelumab+ axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100)", 2019 American Society of Clinical Oncology (ASCO) Annual Meeting (2019), American Society of Clinical Oncology
57. Xu J, "Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer : an open-label, dose escalation and expansion study", Clin Cancer Res, 25, pp.515~523 (2019)
58. Choi C, "Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma", World J Gastroenterol, 25, pp.2416~2429 (2019)
59. 정해일, "Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma", Cancer Research and Treatment, 49(1), pp.246~254 (2017), 대한암학회
60. Hye Won Lee, "Serum PD-1 Levels Change with Immunotherapy Response but Do Not Predict Prognosis in Patients with Hepatocellular Carcinoma", Journal of Liver Cancer, 19(2), pp.108~116 (2019), 대한간암학회[DOI]
61. Liu CQ, "Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma", Br J Cancer, 119, pp.80~88 (2018)
62. Yau T, "Nivolumab(NIVO)+ ipilimumab(IPI)combination therapy in patients(pts)with advanced hepatocellular carcinoma(aHCC) : results from CheckMate 040", J Clin Oncol, 37, pp.4012~ (2019)
63. Cheng AL, "IMbrave150 : efficacy and safety results from a ph III study evaluating atezolizumab(atezo)+ bevacizumab(bev)vs sorafenib(Sor)as first treatment(tx)for patients(pts)with unresectable hepatocellular carcinoma(HCC)", Ann Oncol, 30, pp.ix186~ix187 (2019)
64. Llovet J, "A phase Ib trial of lenvatinib(LEN)plus pembrolizumab(PEMBRO)in unresectable hepatocellular carcinoma(uHCC) : updated results", Ann Oncol, 30, pp.v286~v287 (2019)
65. Zhan C, "Safety of combined yttrium-90 radioembolization and immune checkpoint inhibitor immunotherapy for hepatocellular carcinoma", J Vasc Interv Radiol, 31, pp.25~34 (2020)

관련 논문AI추천